# Formulary Update

The information contained herein is believed to be accurate at the time of posting, but changes may occur at any time without prior notice. Members should refer to their benefit agreement to understand how changes to non-Formulary status may affect them. For additional information regarding their benefits, members should contact Customer Service at the phone number on their ID card.

## Q1 2027 Commercial Drug List Changes

| Drug Name | Essential Direct Drug List 3 Tier | Essential Direct Drug List 4 Tier | Essential Direct Drug List 5 Tier | Effective Date |
|---|---|---|---|---|
| EPCLUSA | Tier 3 → NF | Tier 4 → NF | Tier 4 → NF | 1/1/2027 |
| HARVONI | Tier 3 → NF | Tier 4 → NF | Tier 4 → NF | 1/1/2027 |
| LEDIPASVIR/SOFOSBUVIR | NF -> Tier 3 | NF -> Tier 4 | NF -> Tier 4 | 1/1/2027 |
| SOFOSBUVIR/VELPATASVIR | NF -> Tier 3 | NF -> Tier 4 | NF -> Tier 4 | 1/1/2027 |
| VOSEVI | Tier 3 → NF | Tier 4 → NF | Tier 4 → NF | 1/1/2027 |
| INSULIN GLARGINE-YFGN PEN (NDC: 72572*) [Civica) | NF → Tier 2 | NF → Tier 2 | NF → Tier 2 | 1/1/2027 |

*Members should refer to their member handbook for benefit details regarding applicable copayments or coinsurance

***Please note:*** Drug list/formulary tier status changes impact commercial members using the Essential Direct Drug Lists. The drug tier status changes reflected here do not impact drug coverage for members enrolled in a health insurance exchange or members who have prescription drug coverage through the Affordable Care Act.